DocGo refutes short seller claims; projects 40% revenue growth in FY2023

DocGo Inc.

Select preliminary FY2023 results indicate ~40% revenue growth, following 84% CAGR from 2016-2022.
Claims of Medicare fraud unsubstantiated; company cites routine regulatory reviews with no adverse findings.
Company says $100M liability claim in ABC liquidation of California subsidiary is incorrect; actual liability is not $100M.
DocGo emphasizes VIE structure is standard and consolidated; no Enron-like fraud.
Company sent cease-and-desist to Fuzzy Panda and explores legal recourse.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

DocGo Inc. reported preliminary financial results for fiscal year 2023.

Period: fiscal year 2023
Result: preliminary results

Exact text from the filing

select preliminary financial results for fiscal year 2023

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

DocGo Inc. filing history →

Source: SEC EDGAR

accession 0001822359-24-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.